Discovering novel carbonic anhydrase type IX (CA IX) inhibitors from seven million compounds using virtual screening and in vitro analysis

References

• Thiry A, Dogné JM, Masereel B, Supuran CT. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 2006;27:566–73
   PubMed Web of Science ®Google Scholar
• Pastorek J, Pastoreková S, Callebaut I, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994;9:2877–88
   PubMed Web of Science ®Google Scholar
• Balaydin HT, Durdagi S, Ekinci D, et al. Inhibition of human carbonic anhydrase isozymes I, II and VI with a series of bisphenol, methoxy and bromophenol compounds. J Enzyme Inhib Med Chem 2012;27:467–75
   PubMed Web of Science ®Google Scholar
• Ekinci D, Kurbanoglu NI, Salamci E, et al. Carbonic anhydrase inhibitors: inhibition of human and bovine isoenzymes by benzenesulphonamides, cyclitols and phenolic compounds. J Enzyme Inhib Med 2012;27:845–8
   PubMed Web of Science ®Google Scholar
• Ekinci D, Al-Rashida M, Abbas G, et al. Chromone containing sulfonamides as potent carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;27:744–7
   PubMed Web of Science ®Google Scholar
• Cavdar H, Ekinci D, Talaz O, et al. alpha-Carbonic anhydrases are sulfatases with cyclic diol monosulfate esters. J Enzyme Inhib Med Chem 2012;27:148–54
   PubMed Web of Science ®Google Scholar
• Senturk M, Ekinci D, Goksu S, Supuran CT. Effects of dopaminergic compounds on carbonic anhydrase isozymes I, II, and VI. J Enzyme Inhib Med Chem 2012;27:365–9
   PubMed Web of Science ®Google Scholar
• Ekinci D, Karagoz L, Ekinci D, et al. Carbonic anhydrase inhibitors: in vitro inhibition of α isoforms (hCA I, hCA II, bCA III, hCA IV) by flavonoids. J Enzyme Inhib Med Chem 2013;28:283–8
   PubMed Web of Science ®Google Scholar
• Ozdemir ZO, Senturk M, Ekinci D. Inhibition of mammalian carbonic anhydrase isoforms I, II and VI with thiamine and thiamine-like molecules. J Enzyme Inhib Med Chem 2013;28:316–19
   PubMed Web of Science ®Google Scholar
• Abdel-Aziz AA-M, El-Azab AS, Ekinci D, et al. Investigation of arenesulfonyl-2-imidazolidinones as potent carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2015;30:81–4
   PubMed Web of Science ®Google Scholar
• Korkmaz N, Obaidi OA, Senturk M, et al. Synthesis and biological activity of novel thiourea derivatives as carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2015;30:75–80
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Parkkila S, Zavada J. Tumor-associated carbonic anhydrases and their clinical significance. Adv Clin Chem 2006;42:167–216
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Beasley NJP, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075–83
   PubMed Web of Science ®Google Scholar
• Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumor hypoxia, survival pathway and therapy target. Cell Cycle 2004;3:164–7
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146–89
   PubMed Web of Science ®Google Scholar
• Swietach P, Wigfield S, Cobden P, et al. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem 2008;283:20473–83
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases as drug targets – an overview. Curr Top Med Chem 2007;7:825–33
   PubMed Web of Science ®Google Scholar
• Alterio V, Hilvo M, Di Fiore A, et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci USA 2009;106:16233–8
   PubMed Web of Science ®Google Scholar
• Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res 2000;28:235–42
   PubMed Web of Science ®Google Scholar
• (a) Schrödinger Suite 2012 Protein Preparation Wizard; Epik version 2.3. New York (NY): Schrödinger, LLC; 2012. (b) Impact version 5.8. New York (NY): Schrödinger, LLC; 2012. (c) Prime version 3.1. New York (NY): Schrödinger, LLC; 2012
   Google Scholar
• Mårtensson L-G, Karlsson M, Carlsson U. Dramatic stabilization of the native state of human carbonic anhydrase II by an engineered disulfide bond. Biochemistry 2002;41:15867–75
   PubMed Web of Science ®Google Scholar
• Li H, Robertson AD, Jensen JH. Very fast empirical prediction and rationalization of protein pK a values. Proteins Struct Funct Genet 2005;61:704–21
   PubMed Web of Science ®Google Scholar
• Bas DC, Rogers DM, Jensen JH. Very fast prediction and rationalization of pKa values for protein-ligand complexes. Proteins Struct Funct Genet 2008;73:765–83
   PubMed Web of Science ®Google Scholar
• Olsson MHM, SØndergaard CR, Rostkowski M, Jensen JH. PROPKA3: Consistent treatment of internal and surface residues in empirical p K a predictions. J Chem Theory Comput 2011;7:525–37
   PubMed Web of Science ®Google Scholar
• Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. J Mol Graph 1996;14:33–8
   PubMed Web of Science ®Google Scholar
• Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J Comput Chem 2005;26:1781–802
   PubMed Web of Science ®Google Scholar
• Zhu X, Lopes PEM, Mackerell AD. Recent developments and applications of the CHARMM force fields. Wiley Interdisciplinary Rev 2012;2:167–85
   Google Scholar
• Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47:1739–49
   PubMed Web of Science ®Google Scholar
• Suite 2012: Glide, version 5.8. New York (NY): Schrödinger, LLC; 2012
   Google Scholar
• Suite 2012: LigPrep, version 2.5. New York (NY): Schrödinger, LLC; 2012
   Google Scholar
• Irwin JJ, Shoichet BK. ZINC – a free database of commercially available compounds for virtual screening. J Chem Inf Model 2005;45:177–82
   PubMed Web of Science ®Google Scholar
• QikProp, version 3.5. New York (NY): Schrödinger, LLC; 2012
   Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3–26
   PubMed Web of Science ®Google Scholar
• Verpoorte JA, Mehta S, Edsall JT. Esterase activities of human carbonic anhydrases B and C. J Biol Chem 1967;242:4221–9
   PubMed Web of Science ®Google Scholar
• Lineweaver H, Burk D. The determination of enzyme dissociation constants. J Am Chem Soc 1934;56:658–66
   Web of Science ®Google Scholar
• Puşcas I, Reznicek A, Moldovan A, et al. Activation of carbonic anhydrase by beta-adrenergic agonists and inhibition by beta-adrenergic blockers. Med Interne 1985;23:185–9
   PubMedGoogle Scholar
• Turkmen H, Durgun M, Yilmaztekin S, et al. Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic isozymes I and II, and the tumor-associated isozyme IX. Bioorganic Med Chem Lett 2005;15:367–72
   PubMed Web of Science ®Google Scholar
• Maresca A, Temperini C, Pochet L, et al. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem 2010;53:335–44
   PubMed Web of Science ®Google Scholar
• Innocenti A, Gülçin I, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorganic Med Chem Lett 2010;20:5050–3
   PubMed Web of Science ®Google Scholar
• Winum JY, Pastorekova S, Jakubickova L, et al. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorganic Med Chem Lett 2005;15:579–84
   PubMed Web of Science ®Google Scholar
• Winum JY, Innocenti A, Scozzafava A, et al. Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isoforms I and II and transmembrane, tumor-associated isoforms IX and XII with boronic acids. Bioorganic Med Chem 2009;17:3649–52
   PubMed Web of Science ®Google Scholar
• Durdagi S, Sentürk M, Ekinci D, et al. Kinetic and docking studies of phenol-based inhibitors of carbonic anhydrase isoforms I, II, IX and XII evidence a new binding mode within the enzyme active site. Bioorganic Med Chem 2011;19:1381–9
   PubMed Web of Science ®Google Scholar
• Pacchiano F, Carta F, McDonald PC, et al. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J Med Chem 2011;54:1896–902
   PubMed Web of Science ®Google Scholar
• Mavromoustakos T, Durdagi S, Koukoulitsa C, et al. Strategies in the rational drug design. Curr Med Chem 2011;18:2517–30
   PubMed Web of Science ®Google Scholar
• Politi A, Durdagi S, Moutevelis-Minakakis P, et al. Development of accurate binding affinity predictions of novel renin inhibitors through molecular docking studies. J Mol Graph Model 2010;29:425–35
   PubMed Web of Science ®Google Scholar
• Durdagi S, Scozzafava GL, Vullo D, et al. Inhibition of mammalian carbonic anhydrases IXIV grayanotoxin III: solution and in silico studies. J Enzyme Inhib Med Chem 2013;29:469–75
   PubMed Web of Science ®Google Scholar
• Ekinci D, Fidan I, Durdagi S, et al. Kinetic and in silico analysis of thiazolidin-based inhibitors of α-carbonic anhydrase isoenzymes. J Enzyme Inhib Med Chem 2013;28:370–4
   PubMed Web of Science ®Google Scholar